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Long term continuous hepatic artery infusion of FUDR was carried out in 34 rats. In the animals who
received a constant infusion schedule of 15mg/kg/day all died of toxicity with a mean survival of 9.3 days.
If the pattern of the continuous infusion was changed so that over 60% of the infusion was given during
the hours of 3pm to 9pm then all of the animals survived the 14 day infusion. If the maximum dose of
infusion was changed so that 60% of the infusion was given at night from 3am to 9am the infusion
became more toxic and all the animals died in a mean of 5.5 days. Pathologic sectioning of al! the livers
reflected the above outcomes with the greatest amount of hepatic necrosis in the animals on the night
cycles. This study underscores the recent advances in chronobiology demonstrating that for continuous
hepatic arterial infusions the timing of delivery is crucial in determining the toxicity.
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INTRODUCTION
Continuous hepatic artery infusion of FUDR has been studied in patients with
colorectal metastases to the liver for the past 10 years. It is still the therapy that has
the best response rates in these clinical situations, but many clinicians fear its use
because of the severe and often fatal biliary toxicities associated with this treat-
ment. Specifically biliary sclerosis, sometimes referred to as sclerosing cholangitis,
can result after continuous hepatic artery infusion(CHAI) of floxuridine(FUDR)1.
Although the complication is dose related, some patients develop biliary sclerosis
even at the lowest dose of 0.1 mg/kg/d. Clearly a method to reduce this toxicity
would enhance the usefulness ofCHAI ofFUDR. There has been a suggestion that
using a circadian rhythm for the CHAI can lower the toxicity. Previous experiments
were done in rats using an intravenous approach which did show a decrease of the
toxicity of infusion for rats given a circadian pattern with the greatest amount given
during the afternoon hours2. The present study utilizes a rat model which is
identical to the human CHAI model. The rats all have hepatic artery catheters
through which continuous infusions can be performed for 14 days, which is the
same amount of time as the human perfusions. Using this model we studied the
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effects that changing flow rates of the FUDR had on the toxicity to the liver
parenchyma.
MATERIAL AND METHOD
Sixteen Sprague Dawley and 18 Fisher rats were kept in the St. Vincent’s Medical
Center animal facility, on rat chow, in an 8am to 8pm lights on and 8pm to 8am
lights off routine. Each rat underwent a laparotomy for placement of a #10
Polyethylene tube(Clay Adams) for hepatic artery infusion. The average rat was
250 gm at the time of the operation and eight weeks old. The catheter was placed
into the gastroduodenal artery and the artery was ligated distally. The catheter Was
then passed through the abdominal fascia, tunnelled under the skin to an. opening
between the scapulae. At that spot a metal button was placed subcutaneously with
a coiled metal catheter attached (Instatech). The PE catheter was passed through
the button into the coiled metal tube and was attached to a swivel placed above the
rat’s cage. This swivel was connected to the infusion pump. This arrangement
allowed the rat free mobility in its cage, as well as protecting the button apparatus.
For additional protection, a small jacket was placed on the rat, preventing it from
chewing on the catheter exit site.
The infusion pumps used were the portable Intelliject pumps with a computer
programmable chip for a varied infusion cycle. The accuracy of flow rates were
verified before use.
Eleven rats were placed on a constant infusion cycle ofFUDR (Roche) at 15 mg/
kg/day. The infusion was started 24 hours after the operation for placement of the
catheter. Eleven rats were placed on a "day" cycle of infusion. In these animals a
total dose of 15 mg/kg/day of FUDR was given in a volume of 4 cc/day. The
infusion schedule was as follows: From 9am to 3pm 0.6cc was infused(0.1cc/hr),
from 3pm to 9pm 2.7cc(0.45cc/hr) was infused, from 9pm to 3am 0.6cc(0.1cc/hr)
was infused and from 3am to 9am 0.08cc(.013cc/hr) was infused (see Table 1).
Twelve rats received 15 mg/kg/day ofFUDR on a "night" cycle again in a volume of
4cc/d. These animals received 0.6cc from 9am to 3pm, 0.08cc from 3pm to 9pm,
2.7cc from 9pm to 3am and 0.6cc from 3am to 9am (see Table 2). All the infusions
were given for 14 consecutive days or until the animal died if less than 14 days. The
animals that survived the 14 day FUDR infusion were then infused with heparin
and saline for 14 more days at which time they were sacrificed.
The livers of all the animals were excised and fixed in 10% neutral buffered
formalin prior to pathological examination. All livers were sectioned at 3 mm
intervals with no less than 2 blocks submitted for paraffin sections, which included
any grossly visible lesion as well as representative hepatic parenchyma. A minimum
of 4 cm2 crosssectional area was examined histologically in each case. Hematoxylin
and Eosin (H&E) stained sections were examined by two independent pathologists
utilizing conventional light microscopy.
RESULTS
All of the 11 animals on the constant infusion ofFUDR died in 6 to 12 days with a
mean survival of 9.3 days + 1.7(Table 3). Seven of these animals were Fisher ratsHEPATIC ARTERY INFUSION 187
Table 1
CIRCADIA.N DOSAGE
Day Cycle
9am-3pm 3pm-9pm 9pm-3am 3am-9am
Time
Dosage Given/mg
with a mean survival of 9.3+ 1.8 days. The other 4 were Sprague Dawley rats with
a mean survival of 9.25 + 1.7 days. There was no significant difference in survival
of these two strains. The rats began to look ill several days before their deaths.
Most had mouth sores with ulcerations, eye infections and some bleeding per
rectum.
All of the 11 animals who received the "day" cycle infusions survived the 14 days
of infusion. One of the animals died one day later (day 15) of hemorrhagic colitis,
while the 10 other animals were all sacrificed 15 days after the end of the 14 day
infusion. None of these rats seemed ill, with no mouth ulcerations or eye problems.
In the "night" cycle infusion group all 12 animals died between 4 to 7 days with a
mean survival of 5.5 + 1.2 days. Again these rats seemed to have the same physical
problems as the constant flow group with mouth ulcerations, eye infections and
rectal bleeding. Half of this group were Fisher rats with a mean survival of 6.2 +
1.2 days. The other half were Sprague Dawley rats with a mean survival of 4.8 + 1.
There was no statistically significant difference between the survival in these two
strains..188 M.M. KEMENY ETAL.
Table 2
CIRCADIAN DOSAGE
Night Cycle
9am-3pm 3pm-9pm 9pm-3am 3am-9am
Time
Dosage Given/mg
The group with the day cycle had the best response since none of the rats died of
toxicity during the infusion. There was a statistically significant difference in the
survival of the animals on the night cycle versus the constant infusion (Paired t-test
p < .0001). The group treated with the night cycle had a poorer survival.
PATHOLOGY
The livers from rats who had received a constant continuous infusion of FUDR
were noted to contain rare portal chronic inflammatory cells and minimal centrilo-
bular congestion as well as small degenerative foci within lobules. The general
architecture appeared preserved with foci of single hepatocyte necrosis, swelling
and vacuolization. Multifocal microvacuolar fatty changes were noted, predomi-
nantly in the centrilobular areas (Figure 1). For rats who had received a circadian
timed day infusion of FUDR their livers had rare foci of hepatocyte swellingHEPATIC ARTERY INFUSION 189
Table 3
100%
50%
SURVIVAL CURVES IN RATS RECEIVING
CONTINUOUS HEPATIC ARTERY INFUSIONS
OF FUDR (15mg/kg/d)
Night Cycle
Continuous
Day Cycle
2 3 4 5 6 7 8 9 10 11 12 13 14 15
DAYS
without evidence of vacuolar degeneration or single cell necrosis. No inflammatory
infiltrates were noted (Figure 2). The livers in the rats who received a timed
infusion ofFUDR with the majority of the drug given at night had multifocal broad
areas of necrosis some of which were extensive without identifiable zonal predilec-
tion. There was also extensive vacuolar degeneration with macrovacuolar fatty
change predominantly in centrilobular areas. There was marked centrilobular
chronic passive congestion. No significant lobular or portal inflammatory response
was noted. A mild, diffuse, Kupffer cell hyperplasia was identified in those cases
with extensive necrosis (Figure 3).
All livers lacked evidence of granulomas, eosinophilic inclusions, bile duct
proliferation, sclerosis, fibrosis, bile plugs, cholestasis, vacuolar abnormalities or
hepatocyte dysplasia.
DISCUSSION
The concept that there are chemical changes in the body’s ability to metabolize
drugs that are dependent on a 24 hour or circadian rhythm is not new. Even
scientists in the 15th century realized that there were physiologic changes that
paralleled daily cycles. However this knowledge of chronobiology had not been
utilized in the treatment of cancer with toxic chemotherapy until very recently.
Now there are numerous clinical and animal studies showing that circadian timing
of chemotherapy administration can decrease drug toxicity3-. A study from France
in 1987 showed that patients receiving a continuous infusion of 5-fluorouracil (5FU)190 M.M. KEMENY ET AL.
Figure 1 This section from a liver of an animal receiving a congtant continuous infusion of FUDR
(Magnification 40, H & E stain) shows a centrilobular area with hepatocyte swelling, vascular
congestion, and foci of necrosis.
Figure 2 This section from a liver of an animal receiving a circadian timed day infusion of FUDR
(Magnification 470 x, H & E stain) shows mild fatty and degenerative changes and vascular congestion,HEPATIC ARTERY INFUSION 191
Figure 3 This section from a liver of an animal receiving a circadian timed night infusion of FUDR
(Magnification 40 x, H & E stain) shows a peripheral section of liver with a broad zone of necrosis and
fatty changes in non necrotic hepatocytes.
at a constant rate had varying plasma concentrations of the drug depending on the
time of day. The lowest concentrations were seen during the daylight hours and the
highest were at 12 midnight. There was a definite circadian pattern to the
concentrations suggesting more absorption and metabolism during the day. Since
the liver was the main organ of clearance of 5-FU this finding suggested a circadian
pattern to hepatic metabolism9.
When these concepts were utilized in patterning chemotherapy infusions new
information on toxicity was obtained. A study of a continuous intravenous infusion
of FUDR given to rats with a maximal daytime dose and minimal night dose was
found to be less toxic than on a constant continuous infusion2.
Toxicity is of key importance in the clinical setting when continuous hepatic
artery infusion of FUDR is used for hepatic metastases. Implantable pumps have
been used for over 10 years to get response rates of over 50% in patients with
hepatic metastases from colorectal cancer1’11. No other modality at this time
produces comparable responses in hepatic metastases. The main reason that
hepatic infusion has not been universally adopted as the treatment of choice for
colorectal metastases to the liver is because of the incidence of biliary sclerosis
associated with therapy. It is now felt that approximately 20% of patients getting
11011 CHAI will develop biliary sclerosis Consequently, decreasing this incidence of
toxicity would greatly enhance the value of CHAI ofFUDR. Previous experiments
in rats have shown that intravenous FUDR given by a continuous constant flow was192 M.M. KEMENY ETAL.
more toxic than the same drug given in a circadian daytime pattern2’8’12. Diarrhea
was the toxicity being studied. This work was then extrapolated to the intrahepatic
artery infusions of FUDR. However the intraarterial situation is quite different
since biliary sclerosis, not diarrhea, is the toxicity. Also, infusing the hepatic artery
is anatomically unique because of the dual blood supply of hepatocytes. At least
70% of hepatic afferent flow comes from the portal vein; hence, a continuous
hepatic artery infusion may not have a strong impact on normal hepatocytes.
However, hepatic neoplasms derive 90% of their blood supply from the hepatic
artery, not the portal vein. Shunting may occur into the normal hepatic vasculature
exposing more hepatocytes to the continuous infusion. Because of this uniqueness,
an animal model of continuous hepatic infusion of FUDR was needed to study
toxicity.
In this study a rat model was used where the animals were infused via an hepatic
artery catheter for the same 14 day cycle that is used for patients. When rats were
infused with CHAI of FUDR at doses 50 times the level of human doses the rats
suffer a toxic death which is marked by hepatic necrosis, diarrhea and mucositis. If
the same dose is given by use of circadian patterning with over 50% of the dose
delivered betwee 3pm and 9pm in the afternoon none of the rats died. With this
minimal change in flow patterning there is a dramatic decrease in toxicity. When
the circadian patterning was switched to a cycle where most of theFUDR was given
at night (night cycle) not only did all the animals die but they died in a statistically
significantly shorter interval than the animals receiving a constant rate infusion.
This study underscores the importance of circadian timing especially in con-
tinuous infusional therapy. A uniformly fatal dose ofFUDR can be tolerated if the
drug is given on what we term a day cycle. Survival and liver pathology are greatly
improved with this type of cycling. In addition, it appears that night cycling is more
toxic than a flat rate; further evidence supporting the concept of timing,
The exact mechanism of this response is unclear but it suggests that there may be
circulating factors which are dependent on diurnal variation. Steroids would
certainly be a consideration since they are known to increase hepatic catobolism of
toxic substances.
The next step is to look at this patterning of FUDR in a tumor bearing host to
evaluate if the decreased toxicity is a trade off for decreased tumor response.
Experiments are underway to test this hypothesis.
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INVITED COMMENTARY
This study corroborates previous findings that circadian timing of cytostatic drug
administration may affect toxicity. This is an interesting observation that may be
utilized in the clinical setting.
In the present study toxicity may have been lower at daytime than at night
because of (1) increased catabolism of the drug, (2) altered effect(s) of the drug at
the cellular level or (3) a relatively high ability to repair cellular damage. Petit et al.
demonstrated that plasma concentrations of 5-ttuorouracil (5-FU) were higher at
night than at daytime in patients receiving a continuous infusion for 5 days1,
indicating that there is a diurnal variation of the metabolism of 5-FU.
Increased antineoplastic activity and reduced toxicity are crucial elements in
cytostatic drug therapy. A possible way to increase selectivity is to administer the
drug at a time of the day when tolerance is relatively good, an approach made
practical by the development of implantable and programmable infusion systems.
However, circadian patterning of drug infusion is going to be advantageous only if
there is a difference between neoplastic and normal cells with respect to one or
more of the possible mechanisms for altered toxicity. It appears reasonable to
assume that malignant cells are less susceptible to circadian changes than normal
cells, and this has been proven in animal models2. In addition, there may be a
circadian variation in the effect of cytostatic drugs on malignant cells. Thus, it has
been shown that there is a marked, dose-independent circadian difference in the
ability of doxorubicin-cisplatin or FUDR to produce tumour response and cure in
rats with transplanted plasmacytoma or adenocarcinoma2’3.194 M.M. KEMENY ETAL.
There is clearly a need for continued studies on the benefits of circadian timing in
cancer chemotherapy. Further studies in animals and, in particular, in patients are
awaited with interest.
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